MNG180
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.446
- PROTEIN_SECRETION+0.355
- ANDROGEN_RESPONSE+0.232
- MITOTIC_SPINDLE+0.213
- INTERFERON_ALPHA_RESPONSE+0.181
- G2M_CHECKPOINT+0.161
- HEME_METABOLISM+0.152
- MYC_TARGETS_V1+0.140
- NOTCH_SIGNALING+0.138
- PI3K_AKT_MTOR_SIGNALING+0.098
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.427
- ANGIOGENESIS-0.337
- CHOLESTEROL_HOMEOSTASIS-0.308
- MYOGENESIS-0.300
- HYPOXIA-0.274
- COAGULATION-0.257
- OXIDATIVE_PHOSPHORYLATION-0.257
- MYC_TARGETS_V2-0.244
- ALLOGRAFT_REJECTION-0.243
- INFLAMMATORY_RESPONSE-0.227
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD032426_D1.RNA-Seq | EPN | Anaplastic EPN | 0.758 |
| 2 | R337 | — | — | 0.727 |
| 3 | TCGA-BH-A0W3-01A-11R-A109-07 | — | B | 0.720 |
| 4 | MDT-AP-3288 | Med | Medulloblastoma | 0.714 |
| 5 | R357 | — | — | 0.710 |
| 6 | SRR3147748 | — | — | 0.706 |
| 7 | MNG1173 | — | — | 0.699 |
| 8 | TCGA-E2-A10A-01A-21R-A115-07 | — | B | 0.699 |
| 9 | MDT-AP-3205 | Med | Medulloblastoma | 0.697 |
| 10 | MNG573 | — | — | 0.696 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.446 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.355 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.232 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.213 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.181 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.161 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.152 | Temsirolimus | — uncovered |
| MYC_TARGETS_V1 | 0.140 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.138 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.098 | Inavolisib | — uncovered |
| APOPTOSIS | 0.091 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.083 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.082 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.069 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.059 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.046 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.035 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.030 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.026 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.007 | Cobimetinib | — uncovered |